Ignite Creation Date:
2024-05-06 @ 3:50 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04777162
Status:
UNKNOWN
Last Update Posted:
2021-03-04
First Post:
2021-02-25
Brief Title:
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
Sponsor:
Peking University
Organization:
Peking University
Study Overview
Official Title:
Efficacy and Safety of Tislelizumab Plus Anlotinib in PD-1PD-L1 Resistant Metastatic Gastric or Colorectal Cancer a Single Arm Phase II Clinical Trial
Status:
UNKNOWN
Status Verified Date:
2021-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Immunotherapy acquired resistance was observed in clinical practice The investigators intended to add anlotinib to PD-1 inhibitors hoping reverse the resistance
Detailed Description:
Anti-angiogenesis seems have positive effects on tumor immune microenvironment the combination of PD-1PD-L1 inhibitors and TKIs exhibited favorable efficacy on gastrointestinal malignancies Here the investigators want to examine the efficacy and survival benefit from the combination therapy to PD-1 acquired resistance patients which turns out to be critical issues in recent years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None